Tag Archive for: M&A

Roche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin, an FGF21 analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). The deal is expected to close in Q4 2025.

CSL has signed an option and collaboration agreement with VarmX valued at up to US$2.2bn. The company will pay US$117m upfront and will fund a global Phase III trial of VMX-C001.

RWK Bidco AB, newly founded by the private equity firm KKR (Kohlberg Kravis Roberts & Co.), has identified Swedish separation specialist Biotage AB as a takeover target and submitted an official takeover offer.

Genentech, the US arm of Swiss-based Roche AG, plans to acquire its long-time partner in allogeneic CAR-T blood cancer and gene therapies, Poseida Therapeutics Inc, for up to US$1.5bn.

Lundbeck A/S is set to take over all shares of neurology specialist Longboard Pharmaceuticals Inc worth US$2.6bn to strengthen its pipeline with the Phase III 5-hydroxythyprytamaine 2C receptor super-agonist bexicaserine to treat 11 rare neurological conditions.

© NicoElNino - stock.adobe.com

Danish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis.

© Calluna Pharma, edited by BIOCOM

Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.

© Jabri & Abadie Nat.Rev.Immunol 2015; Waldmann et al. J. Exp. Med 2019; Created with BioRender

Calypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up to US$175.

Discovery Center of AstraZeneca @AstraZeneca

Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.

ADC in action, illustration by @ImmunoGen Inc.

AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.